Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report

Treatment of anaemia and reduction of transfusion are major therapeutic goals in patients with low-risk myelodysplastic syndrome (MDS). Although erythropoiesis-stimulating agents (ESAs) are widely used to reduce transfusion requirement, ESAs lose effectiveness within 12 months. We report a 65-year-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikenoue, Tatsuyoshi, Furumatsu, Yoshiyuki, Kitamura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143669/
https://www.ncbi.nlm.nih.gov/pubmed/34055362
http://dx.doi.org/10.1093/omcr/omab026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143669/
https://www.ncbi.nlm.nih.gov/pubmed/34055362
http://dx.doi.org/10.1093/omcr/omab026

Ejemplares similares